| Autor: |
Hubeek I; Department of Pediatric Oncology/Hematology, VU University Medical Center, Amsterdam, The Netherlands. isabelle.hubeek@vumc.nl, Comijn EM, Van der Wilt CL, Merriman RL, Padron JM, Kaspers GJ, Peters GJ |
| Jazyk: |
angličtina |
| Zdroj: |
Oncology reports [Oncol Rep] 2008 Jun; Vol. 19 (6), pp. 1517-23. |
| DOI: |
10.3892/or.19.6.1517 |
| Abstrakt: |
N-acetyl-dinaline (CI-994) is an investigational anti-cancer drug which inhibits histone deacetylases. We evaluated the interaction between CI-994 and conventional chemotherapeutics used in acute myeloid leukemia (AML) in a rat model for AML and Brown Norway rat acute myelocytic leukemia (BNML). In vitro, CI-994 in combination with cytarabine (ara-C), daunorubicin and mitoxantrone, resulted in moderate synergism. In vivo, higher dosages of CI-994 induced complete remissions. CI-994/ara-C was very active against BNML. The combinations of CI-994/daunorubicin and CI-994/mitoxantrone were also active against BNML. This study demonstrates favorable in vitro and in vivo interactions between CI-994 and conventional anti-cancer agents used for the treatment of AML. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
